body schreef:
'Wijsheid'...
Presentatie door CEO Pharming AVA 2009 (kun je desgewenst zelf even opzoeken op Pharmings site...):
Outlook 2010
•Opinion on European MAA in June
•First product sales for Rhucin in EU
•Clarity on BLA filing and review process for Rhucin in USA in H1
•Start phase II clinical study for rhC1INH in first transplant related indication (AMR in kidney transplantation)
•Continue preparation of phase II clinical study for rhC1INH in DGF in kidney transplantation
•Pre-clinical development of rhC1INH for other reperfusion injury related indications
"Clarity on BLA filing and review process for Rhucin in USA" in H1: Dás toch écht nlt morgen....
Lichaam